Coronavirus Expert on mRNA Vaccines Versus The Old Fashioned Approach
Fool.com's Healthcare and Cannabis Bureau Chief Corinne Cardina interviewed Richard Horton on Motley Fool Live on Oct. 9. Horton runs the British medical journal The Lancet and has been at the forefront of publishing data about the coronavirus pandemic this year. He also recently published a book called The COVID-19 Catastrophe.
Here, Horton explains how investors should think about mRNA coronavirus vaccine candidates from Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), and Moderna (NASDAQ: MRNA) versus potential vaccines that take the more traditional approach.
Source Fool.com
